Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...

Nektar Therapeutics is advancing Rezpeg in atopic dermatitis and alopecia areata. Click here for key insights on NKTR's ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

Here are the top 5 most-viewed alopecia content in 2025.

Nektar Therapeutics released data from a study of its rezpegaldesleukin drug, establishing proof-of-concept in patients with severe to very severe alopecia areata, a hair-loss condition.

Nektar Therapeutics may have a pipeline-in-a-drug with rezpegaldesleukin, has additional readouts ahead, and cash until 2027.

US biotech Nektar Therapeutics shares increased by 10% in pre-market trading following promising Phase IIb trial results.

Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...

Kristen Whitney, DO, FAAD, determines systemic treatment options for severe alopecia areata based on the patient’s medical history, past treatments tried, potential adverse events, in addition to the ...

Nektar Therapeutics (NASDAQ:NKTR) reported results from its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata, with the trial narrowly ...

Alopecia areata is an autoimmune disorder that usually results in unpredictable, patchy hair loss. Approximately 7 million people in the U.S. have alopecia areata, and it can affect anyone of any age ...

A new study shows that one in three patients with a severe skin disease were able to regrow hair after being treated with a common arthritis drug. The study is based on Phase 3 clinical trials using ...